Biotech News
Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa
Study did not meet primary endpoint of percentage change from baseline in total abscess and inflammatory nodule (AN) count at Week 16 Key secondary endpoints, including HiSCR50 and HiSCR75, were not met Both doses of tibulizumab were well tolerated; observed safety was consistent with established
